Moringa May be an Essential Tool in the Fight Against the Global Pandemic

The global moringa products market could be worth up to $8.4 billion by 2026 from $5 million in 2019. All thanks to its anti-depressant, anti-fungal, and anti-viral properties that can play a vital role in curing various diseases, such as those seen with the pandemic. In fact, according to Facts and Factors, “Various parts of the moringa tree such as bark, fruit, root, leaves, flowers, and seeds are used to make medicine and various products with health beneficial and medicinal properties. It is a fast-growing and drought-resistant tree full of minerals and supporting vitamins.” Plus, moringa can help reduce blood sugar, lower cholesterol, treat depression, anxiety, and stress, in addition to its anti-bacterial and anti-fungal properties. Its medicinal qualities could be of great importance to companies fighting the current health pandemic, like Gilead Sciences Inc. (NASDAQ:GILD), Moderna Inc. (NASDAQ:MRNA), Pfizer Inc. (NYSE:PFE), and Novavax Inc. (NASDAQ:NVAX).

It’s also good news for companies like Arev NanoTec Brands Inc. (CSE: AREV)(OTC: AREVF)

AREV produces functional ingredients through its proprietary extraction systems and methods. It’s applying nanotech methods to create premium ingredients for products that have an increased bioavailability. Then, it sells product to targeted natural health, medical, functional food, nutraceutical, sport nutrition markets.

Most recently, Arev NanoTec Brands provided an update on its continued work with natural materials, specifically Moringa. The company has been working with several plant, fungi and marine biomass including functional mushrooms, hops, frankincense, myrrh, Kampot pepper, sea cucumber, ginseng and Moringa.

Much of this work has been focused on the best way to extract actives and researching target compounds present in each of the natural phyto-matierials. As a result, the company has chosen Moringa to be the candidate for molecular screening for its antiviral properties.

The company has secured organic supply from Priceless Farms in Uganda which is working with AREV’s Cambodian subsidiary to establish Moringa as a permaculture crop on its 12 hectare parcel of land near Phnom Penh. The company will continue to update shareholders as progress is made on what is anticipated to be a fast moving initiative.

Mike Withrow CEO of AREV NanoTec stated “We are encouraged by the recommendations of our growing Scientific Advisory Board. They have gone to work quickly and introduced the company to key influential people. The advisory board has been integral in coming up with the direction to explore Moringa.”

Moringa Could be Beneficial to Top Pharmaceutical Companies

Gilead Sciences Inc. (NASDAQ:GILD) and Gritstone Oncology, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.

Moderna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Singapore Health Sciences Authority (HSA) has approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR). “Today’s authorization is another important step in the global fight against COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I want to thank the Singapore Ministry of Health and the HSA for their collaboration and for the confidence they have demonstrated in COVID-19 Vaccine Moderna with this decision.”

Pfizer Inc. (NYSE:PFE), and BioNTech announced  results from in vitro neutralization studies of sera  from individuals vaccinated with the Pfizer-BioNTech COVID-19 vaccine. The sera neutralized SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South Africa variants, as measured by studies conducted by Pfizer and the University of Texas Medical Branch (UTMB). The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal. To study the effect of these mutations, three engineered viruses with key mutations were tested against the panel of human sera from 20 participants in the previously reported Phase 3 trial who had been immunized with the Pfizer-BioNTech COVID-19 vaccine. Of the three recombinant variants, one has a mutation common to both the U.K. and South Africa variants (N501Y), one has mutations common to the U.K. variant (Δ69/70+N501Y+D614G), and the third has mutations common to the South Africa variant (E484K+N501Y+D614G). The sera from individuals vaccinated with the Pfizer-BioNTech COVID-19 vaccine neutralized all the SARS-CoV-2 strains tested.

Novavax Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the company has executed a binding Heads of Terms agreement with the government of Switzerland to supply six million doses of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, to the country. “The government of Switzerland is working proactively to ensure a sufficient supply of our vaccine that could protect its citizens from COVID-19,” said John J. Trizzino, Chief Commercial Officer and Chief Business Officer of Novavax. “Addressing this global public health crisis requires collaboration, and we appreciate their partnership to provide an urgently needed vaccine to stem the pandemic.”

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Arev NanoTec Brands Inc. by a third party. We own ZERO shares of Arev NanoTec Brands Inc. Please click here for full disclaimer.

Contact Information:
[email protected]